Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial.

ABSTRACT:

Background

Neuroinflammation contributes to Parkinson's disease (PD) progression and motor dysfunction. Allogeneic human mesenchymal stem cells (allo-hMSCs) may reduce neuroinflammation and improve motor symptoms.

Objectives

To evaluate the efficacy of repeated intravenous doses of 10 × 10⁶/kg allo-hMSCs in improving motor symptoms in patients with PD (PwP).

Methods

In this phase 2, randomized, placebo-controlled trial (November 2020-July 2023), mild-to-moderate PwP received either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Follow-up lasted 88 weeks. The primary outcome was a >70% posterior probability (PP) of a difference in the proportion of participants with ≥5-point improv

SUBMITTER: Schiess MC 

PROVIDER: S-EPMC12710125 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature